MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$4.07 -0.51%

-$0.02 today

Market cap
$1.31B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 2.12M

Average 5.73M

MNKD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

MannKind CorporationNASDAQ: MNKD

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $5.39M a year earlier. Trailing-twelve-month stock-based compensation was $14.49M.

Context

  • Stock-based compensation amounted to 6.9% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $3.62M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$24.2M+13.3% YoY
LTMMar 2026
$14.49M-36.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+13.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
24.2M USD
Year-over-year change
+13.3%
4-year CAGR
+18.7%

Stock-Based Compensation vs competitors

How MNKD compares with its peers on the latest reported figures

  • MNKD's LTM Mar 2026 stock-based compensation of $14.49M is the 4th largest of the 6 companies compared; the peer median is $18.1M.
  • Its year-over-year change of -36.6% is the lowest of 6, against a peer median of +15.9%.
  • Stock-based compensation amounts to 4.0% of revenue for MNKD, versus a peer median of 16.2%.
MNKD Competitors Peer median
Stock-Based Compensation for MNKD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$24.22M +46.6%+55.8%24.5%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$22.06M +15.9%+22.5%7.0%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$18.1M -14.0%-22.5%16.5%
MNKDMannKind CorporationLTM Mar 2026$14.49M -36.6%—4.0%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$2.28M +4.3%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$367K +43.4%-60.2%16.0%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding MNKD) $18.1M+15.9%-0.0%16.2%

Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(80.93M)(87.4M)(11.94M)27.59M5.86M
Depreciation & Amortization5.47M6.29M5.8M9.04M12.28M
Deferred Income Tax12.64M000(4.97M)
Stock-Based Compensation12.2M017.65M21.36M24.2M
Change in Working Capital(17.73M)(24.05M)14.63M(36.47M)(86.35M)
Accounts Receivables(776K)(11.81M)2.35M2.65M(4.76M)
Inventory(4.08M)(5.67M)4.57M(3.2M)10.4M
Accounts Payables1.37M4.1M(1.47M)(2.79M)(16.71M)
Other Working Capital(14.25M)(10.67M)9.18M(33.14M)(75.27M)
Other Non-Cash Items6.63M24.47M7.96M21M67.23M
Operating Cash Flow(61.71M)(80.7M)34.09M42.51M18.26M
Capital Expenditures(11.47M)(7.59M)(42.44M)(9.69M)(4.57M)
Acquisitions (Net)(56.06M)(15.34M)00(347.74M)
Purchases of Investments(199.13M)(5M)(79.1M)(273.79M)(157.8M)
Sales of Investments59.06M0119.17M58.13M221.72M
Other Investing Activities56.06M32.8M382K128.71M(16.41M)
Investing Cash Flow(151.54M)4.87M(1.99M)(96.65M)(304.8M)
Debt Repayment281.08M(1.09M)(6.86M)(133.17M)325M
Common Stock Issued1.89M22.56M6.89M(6.09M)1.99M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(12.7M)(62K)136.58M1.99M(11.89M)
Financing Cash Flow270.27M21.41M136.61M(137.27M)315.1M
Effect of Forex Changes00000
Net Change in Cash57.02M(54.42M)168.71M(191.4M)28.55M
Free Cash Flow(73.18M)(88.29M)(8.35M)32.82M13.69M

MannKind Corporation

NASDAQ:MNKD

Intrinsic Alpha fair value

Locked

Current Price

$4.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.